Polarean Imaging (GB:POLX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polarean Imaging plc has announced the submission of a supplemental New Drug Application to the FDA seeking approval to lower the minimum age for use of their lung imaging contrast agent XENOVIEW™ to children aged six and older. XENOVIEW™ is currently approved for lung ventilation MRI in adults and children aged 12 and up. The company aims to enhance disease management in younger pediatric patients with this expansion.
For further insights into GB:POLX stock, check out TipRanks’ Stock Analysis page.